TD Cowen analyst Tyler Van Buren maintained a Hold rating on Moderna today and set a price target of $40.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tyler Van Buren has given his Hold rating due to a combination of factors tied to Moderna’s latest quarterly update and the limited incremental information provided. The post–Q4 EPS adjustments to his model, including refreshed assumptions around earnings and profitability, did not materially change his medium‑term risk‑reward view on the stock.
He also updated projected economics for the company’s melanoma candidate, intismeran, but these refinements were not sufficient to justify a more decisive bullish or bearish stance. As a result, he maintains that the shares are fairly balanced between potential upside from the pipeline and uncertainties around execution and future financial performance, supporting a continued Hold recommendation.
In another report released today, TipRanks – Google also reiterated a Hold rating on the stock with a $50.00 price target.